Hemagen Diagnostics, Inc. (HMGN) Research
Hemagen Diagnostics, Inc., a global biotechnology firm, specializes in delivering clinical diagnostic solutions for both human and animal health. The company designs, manufactures, and distributes the VIRGO product line, a series of human clinical immunoassays used for identifying autoimmune and infectious diseases, as well as acute phase proteins. Its comprehensive human diagnostic portfolio also encompasses Universal IFA components, various supplies, controls, calibrators, accessories, H-rotors, reagents, electrodes, equipment, and specialized assays covering conditions such as Chagas, acute phase proteins, and cytokines. For the veterinary market, Hemagen Diagnostics provides diagnostic equipment, reagents, consumables, accessories, and electrodes crucial for chemistry, hematology, and electrolyte analysis. The company reaches a diverse customer base, including laboratories, hospitals, and blood banks, through both direct sales and an extensive distribution network. Established in 1985, Hemagen Diagnostics maintains its headquarters in Columbia, Maryland.
Market snapshot
- Symbol
- HMGN
- Price
- $0.00
- Day change
- 0.00%
- Market cap
- $4.7K
- P/E ratio
- -0.01x
- 52-week range
- 0.0001-0.1251
- Sector
- Healthcare
- Industry
- Biotechnology
Peer companies
Open Hemagen Diagnostics, Inc. (HMGN) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.